New York, NY -- (SBWIRE) -- 01/29/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: MBIA Inc (NYSE:MBI), Oi SA (ADR) (NYSE:OIBR), Antares Pharma Inc (NASDAQ:ATRS), Inovio Pharmaceuticals Inc (NYSEMKT:INO)
MBIA Inc (NYSE:MBI) showed a volume of 1.77million shares by the end of last trade whereas the average volume of the stock remained 2.44 million shares. The stock opened the session at $11.12 but then moved to $11.10. At that price, the stock showed a positive performance of 0.27%. MBIA Inc. (MBIA) together with its consolidated subsidiaries, operates the financial guarantee insurance businesses in the industry and is a provider of asset management advisory services. These activities are managed through three business segments: United States public finance insurance, structured finance and international insurance, and advisory services.
Will MBI Continue To Move Higher? Find Out Here
Oi SA (ADR) (NYSE:OIBR) opened the session at $1.64 and closed the session at $1.66. Traded with volume of 1.74 million shares in the prior session and the average volume of the stock remained 4.14 million shares. Oi SA, formerly Brasil Telecom SA, is a Brazil-based holding company engaged in the provision of Switched Fixed-line Telephony Services (STFC) domestically and internationally. The Company operates in three segments: the Fixed-line telephony/data segment,
Is OIBR a Solid Investment at These Levels? Read This Report For Details
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.39 and closed the session at $4.44. The stock showed a positive performance of 0.68% in previous trading session. Traded with volume of 1.72 million shares in the prior session and the average volume of the stock remained 1.62 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors.
Why Should Investors Buy ATRS After The Recent Gain? Just Go Here and Find Out
Inovio Pharmaceuticals Inc (NYSEMKT:INO) the stock advanced 1.61% and finished the session at $2.53. Traded with volume of 1.72 million shares in the prior session and the average volume of the stock remained 5.62 million shares. The beta of the stock remained 3.26. Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.
Will INO Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)